Study identifier:D8220R00031
ClinicalTrials.gov identifier:NCT04964908
EudraCT identifier:N/A
CTIS identifier:N/A
CREEK is a Multicenter Retrospective Study to understand the clinical characteristics, treatment pathway and resource utilization for patients with chronic lymphocytic leukemia in international region.
Chronic Lymphocytic Leukemia
N/A
No
-
All
1088
Observational
18 Years - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Feb 2024 by AstraZeneca
AstraZeneca
-
A Multicenter Retrospective Study to understand the clinical characteristics, treatment pathway and resource utilization for patients with chronic lymphocytic leukemia A retrospective, multi-centre, observational study to describe disease characteristics, treatment patterns, treatment-related outcomes, and resource utilization for Chronic Lymphocytic Leukemia (CLL) patients in multiple international regions
CREEK is a retrospective, observational, registry-based study including patients with an incidental diagnosis of CLL and started treatment (1st line, 2nd line, or Subsequent lines of treatment) within the period between 01 June 2016 and 12 months before data collection as identified from the patient records (from participating hospitals across the GCC States and the International region countries) with at least 12 months of follow-up, after starting on treatment. Moreover, the study will include a pilot cohort in the GCC as an exploratory objective to describe the clinical and patient characteristics for the treatment-naive CLL patient
Location
Location
Cairo, Egypt, Egypt, 11796
Location
Cairo, Egypt, Egypt, 11591
Location
Cairo, Egypt, Egypt, 11566
Location
Manipal, India, India, 560017
Location
Mumbai, India, India, 400012
Location
Hyderabad, India, India, 500082
Location
Kashmir, India, India, 190011
Location
Kuala Lumpur, Malaysia, Malaysia, 59100
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.